Big Pharma M&A Activity Surges in 2026 Due to Patent Expiries and Strategic Acquisitions
Big Pharma is experiencing a surge in mergers and acquisitions in 2026, driven by patent expiries and the need to bolster drug pipelines. The first quarter of 2026 saw $84 billion in biotech M&A deals, up from $44.4 billion in the same period in 2025, marking the strongest start to a year since 2019. Analysts predict the total 2026 biopharma M&A value could exceed $250 billion.
Tickers: $BMY $GILD $LLY $MRK $PFE
Topics: Biotech Deal activity M&A activity Patent expiries Pharmaceutical industry